Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism Nrf2 modulators(Nuclear factor erythroid 2-related factor 2 modulators), STAT3 modulators(Signal transducer and activator of transcription 3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polycystic Ovary Syndrome | Preclinical | IR | 01 Oct 2024 | |
Autoimmune Diseases | Preclinical | CN | 06 Apr 2024 | |
Autoimmune Diseases | Preclinical | CN | 06 Apr 2024 | |
Uveitis | Preclinical | CN | 06 Apr 2024 | |
Uveitis | Preclinical | CN | 06 Apr 2024 |